Articles related to CERVICAL CANCER

In a phase 3 trial, tisotumab vedotin showed a median overall survival of 11.5 months compared to 9.5 months with standard chemotherapy in patients with recurrent cervical cancer, representing a 30% reduction in the risk of death.

In a recent randomized trial comparing radical and simple hysterectomy in patients with low-risk cervical cancer, findings demonstrated that simple hysterectomy was not inferior in preventing pelvic recurrence at 3 years and offered a significant reduction in postoperative urinary complications.

In a major stride for cervical cancer treatment, the FDA-approved pembrolizumab in combination with CRT demonstrates significant improvement in progression-free survival for FIGO 2014 stage III-IVA patients, marking a pivotal change in therapeutic approaches.

The GCIG INTERLACE study has demonstrated a significant improvement in 5-year survival rates in advanced cervical cancer, from 72% to 80%, with the addition of induction chemotherapy to standard-of-care chemoradiation.

Join historian Susan W. Wade, Ph.D., in exploring her personal experience with vulvar cancer and participation in an experimental clinical trial. Wade’s firsthand account offers not only medical insights but a deeper understanding of the patient’s psychological journey and a reflection on the future of oncology treatments.

Dr. Jyoti Mayadev, a professor of Radiation Medicine at University of California San Diego, discussed the treatment of patients with 1B3 cervical cancer at the Society of Gynecological Oncology’s Annual Meeting on Women’s Cancer. The discussion centered around whether to treat patients with primary chemoradiation and brachytherapy or radical surgery. Dr. Mayadev recommends a multidisciplinary approach, but notes that level 1 evidence data from Landoni et al. in 1997 showed no difference in progression-free survivals or overall survivals between radiation therapy and radical hysterectomy in patients with bulky disease, 1B3, and no lymph node disease. Dr. Mayadev discusses the benefits of chemoradiation, including potential toxicity reduction if a patient needs adjuvant therapy after surgery. She also notes that with technologically advanced radiation and brachytherapy, long-term toxicities can be minimized, including genitourinary toxicities at 6-8%, vaginal toxicities at 5%, and fistula at less than 2%. Dr. Mayadev believes that adaptive radiation therapy may further decrease toxicities and increase cure rates for patients with 1B3 cervical cancer. There are ongoing trials for novel therapeutics and adaptive radiation therapy, such as the ARTIA Cervical Trial, which aims to decrease toxicities and collect patient reported outcomes.